Ua hoʻolaha ʻo XNK Therapeutics AB i kēia lā ua mālama ʻia ka mea maʻi mua ma kahi noiʻi lapaʻau Phase II me ka hoʻohana ʻana i ka lāʻau moho hoʻopaʻapaʻa autologous natural killer (NK) o XNK i hui pū ʻia me Sanofi anti-CD38 antibody Sarclisa (Isatuximab).
"ʻO ka loaʻa ʻana o ka mea maʻi mua i mālama ʻia me nā pūnaewele NK i loko o kēia noiʻi lapaʻau he mea koʻikoʻi nui ia i ka hoʻomohala ʻana o kā mākou moho lāʻau alakaʻi," wahi a Johan Aschan, CMO o XNK Therapeutics. "Ke holomua nei ka haʻawina, a ke kakali nei mākou i nā hopena."
ʻO ka mea noiʻi i hoʻomaka, wehe, randomized, hoʻomalu, Phase II study ISA-HC-NK (EudraCT: 2020-000994-26) hoʻohālikelike i ka lāʻau moho alakaʻi o XNK i hui pū ʻia me Sanofi's anti-CD38 antibody Isatuximab me Isatuximab wale nō ma ke ʻano he mālama hoʻohui ʻana ma hope o autologous stem cell transplantation i nā maʻi me ka myeloma lehulehu hou. Hana ʻia ke aʻo ʻana ma ke kula ʻo Karolinska University Hospital ma kāna kahua ʻo Huddinge a hoʻopuni ʻia ma ka huina o 60 mau maʻi me 30 mau maʻi i kēlā me kēia lima lapaʻau.
He aha e lawe ʻia mai kēia ʻatikala:
- “Having the first patient treated with NK cells in this clinical study is an important milestone in the clinical development of our leading drug candidate,”.
- The clinical study takes place at the Karolinska University Hospital at its Huddinge site and encompasses at total of 60 patients with 30 patients in each treatment arm.
- Ua hoʻolaha ʻo XNK Therapeutics AB i kēia lā ua mālama ʻia ka mea maʻi mua ma kahi noiʻi lapaʻau Phase II me ka hoʻohana ʻana i ka lāʻau moho hoʻopaʻapaʻa autologous natural killer (NK) o XNK i hui pū ʻia me Sanofi anti-CD38 antibody Sarclisa (Isatuximab).
